Prime医药
PRME
3.47
-0.14
-3.88%
Prime医药
US · PRME
#3501 按市值排名
上市于 2022
3.47
-0.14
-3.88%
实时 - 追踪5344个代码 - 心跳于282秒前
· 2026-10-16 19:49
✦ 量化股权信号 计算方式说明
减持
- 最近一期（2026/Q3）披露持股的机构数量减少了5家。
- 机构持股总比例下降了11.1个百分点。
机构持股
- 机构持股比例
- 76.11% -11.13pp
- 机构数量
- 226 -5
- 数据截至
- 2026/Q3 较上一报告期
持股变动 vs 资金流向
方向一致机构在上一报告期减持了股份，同时该股在最近20个交易日的主力资金呈净流出——两者方向一致。
机构持股变动数据按季度发布且存在滞后；资金流向数据为每日更新。请将其作为方向性的交叉验证参考，而非精确的择时信号。
持股人类型
Mutual Fund32.83%
VC/PE Fund22.40%
Individual/Insider14.52%
Hedge Fund10.45%
Public Company8.96%
Private Company0.72%
Family Office/Trust0.46%
Government Pension Fund0.16%
Insurance Company0.14%
Other9.37%
主要股东 截至 2026-03-31
David Liu
11.38% · 20.24M 股
GV Management Company, LLC
9.31% · 16.56M 股
Arch Venture Partners, L.P.
6.89% · 12.26M 股
Bristol-Myers Squibb Company
6.19% · 11.01M 股
BlackRock
5.40% · 9.60M 股
ARK Investment Management LLC
4.69% · 8.35M 股
State Street Global Advisors
4.26% · 7.58M 股
Newpath Management, L.P.
3.43% · 6.11M 股
T. Rowe Price Group, Inc.
3.04% · 5.40M 股
Vanguard Capital Management, LLC
2.97% · 5.29M 股
条形长度是相对于此处列出的最大股东而言，并非相对于公司100%股权。
内部人持股
共追踪50份申报 · 40次买入 · 10次卖出
| 姓名 | 职务 | 持股比例 |
|---|---|---|
| David Liu | Co-Founder & Chair of Scientific Advisory Board | 11.38% |
| Keith Gottesdiener | Chief Executive Officer | 2.45% |
| Jeremy Duffield | Chief Scientific Officer | 0.54% |
| Allan Reine | Chief Financial Officer | 0.07% |
| Ann Lee | Chief Technology Officer | 0.06% |
| Richard Brudnick | Chief Business Officer | 0.01% |
| Robert Taylor Nelsen | Independent Director | 0.01% |
| Michael Kelly | Independent Director | -- |
| Kaye Foster-Cheek | Independent Director | -- |
| David Schenkein | Independent Director | -- |
内部人交易 最近的 Form 4 申报记录
| 日期 | 姓名 | 职务 | 类型 | 股数 | 价格 |
|---|---|---|---|---|---|
| 2026-06-04 | Robert Taylor Nelsen | Independent Director | Other Derivative Acquisition | +75,000 | $3.06 |
| 2026-06-04 | Michael Kelly | Independent Director | Other Derivative Acquisition | +75,000 | $3.06 |
| 2026-06-04 | Kaye Foster-Cheek | Independent Director | Other Derivative Acquisition | +75,000 | $3.06 |
| 2026-06-04 | David Schenkein | Independent Director | Other Derivative Acquisition | +75,000 | $3.06 |
| 2026-06-04 | Jeffrey Marrazzo | Director | Other Derivative Acquisition | +75,000 | $3.06 |
| 2026-06-04 | Wendy Chung | Independent Director | Other Derivative Acquisition | +75,000 | $3.06 |
| 2026-06-04 | Thomas Cahill | Independent Director | Other Derivative Acquisition | +75,000 | $3.06 |
| 2026-02-25 | Allan Reine | Chief Financial Officer | Other Derivative Acquisition | +1,300,000 | $4.38 |
| 2026-02-22 | Ann Lee | Chief Technology Officer | Other Derivative Acquisition | +375,000 | $3.34 |
| 2026-02-22 | Carman Alenson | Chief Accounting Officer & Interim CFO | Other Derivative Acquisition | +140,000 | $3.34 |
| 2025-07-31 | Robert Taylor Nelsen | Independent Director | Derivative Sale to Issuer | -84,062 | -- |
| 2025-07-31 | Robert Taylor Nelsen | Independent Director | Other Derivative Acquisition | +84,062 | $4.04 |
| 2025-07-31 | Michael Kelly | Independent Director | Derivative Sale to Issuer | -106,578 | -- |
| 2025-07-31 | Michael Kelly | Independent Director | Other Derivative Acquisition | +106,578 | $4.04 |
| 2025-07-31 | Kaye Foster-Cheek | Independent Director | Derivative Sale to Issuer | -106,578 | -- |
| 2025-07-31 | Kaye Foster-Cheek | Independent Director | Other Derivative Acquisition | +106,578 | $4.04 |
| 2025-07-31 | David Schenkein | Independent Director | Derivative Sale to Issuer | -84,062 | -- |
| 2025-07-31 | David Schenkein | Independent Director | Other Derivative Acquisition | +84,062 | $4.04 |
| 2025-07-31 | Ann Lee | Chief Technology Officer | Derivative Sale to Issuer | -361,990 | -- |
| 2025-07-31 | Ann Lee | Chief Technology Officer | Other Derivative Acquisition | +361,990 | $4.04 |
Form 4 申报记录，每家公司显示最新的一批。"Other Derivative Acquisition"（其他衍生品获取）类目多为限制性股票/期权归属，并非公开市场买入——具体类型见"类型"列。
报价时间 2026-10-16 19:49:46 · 仅供参考，不构成投资建议，也未考虑您的具体情况。
Prime医药 讨论区 0 条评论